Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Defining a New “Mayo Stage IIIc” Ultra Poor Risk Category in Systemic AL Amyloidosis: Incorporating Echocardiographic Global Longitudinal Strain to the European Modified Mayo Staging System

Jahanzaib Khwaja, Sriram Ravichandran, Joshua Bomsztyk, Oliver Charles Cohen, Darren Foard, Ana Martinez-Naharro, Lucia Venneri, Marianna Fontana, Carol Whelan, Philip N Hawkins, Julian Gillmore, Helen J Lachmann, Shameem Mahmood, Amy A Kirkwood, Ashutosh D. Wechalekar

Blood (2024) 144 (Supplement 1): 890.

https://doi.org/10.1182/blood-2024-203527

Published: 2024

Journal Articles

Prognostication in IgM and Lymphoplasmacytic Lymphoma Associated Systemic AL Amyloidosis

Jahanzaib Khwaja, Sriram Ravichandran, Darren Foard, Ana Martinez-Naharro, Lucia Venneri, Marianna Fontana, Carol Whelan, Philip N Hawkins, Julian Gillmore, Helen J Lachmann, Shameem Mahmood, Shirley D'Sa, Ashutosh D. Wechalekar

Blood (2024) 144 (Supplement 1): 4684.

https://doi.org/10.1182/blood-2024-207522

Published: 2024

Journal Articles

Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis

Blood (2024) 143 (13): 1259–1268.

https://doi.org/10.1182/blood.2023022399

Published: 2024

Includes: Supplemental data

Journal Articles

High Responses Rates with Single Agent Belantamab Mafodotin in Relapsed Systemic AL Amyloidosis

Blood (2023) 142 (Supplement 1): 3408.

https://doi.org/10.1182/blood-2023-182042

Published: 2023

Journal Articles

Limited Utility of Mayo 2012 Cardiac Staging System for Risk Stratification of Patients with Advanced Cardiac AL Amyloidosis - Analysis of a Uniformly Treated Cohort of 1275 Patients

Jahanzaib Khwaja, Sriram Ravichandran, Joshua Bomsztyk, Oliver Charles Cohen, Darren Foard, Ana Martinez - Naharro, Lucia Venneri, Marianna Fontana, Philip N Hawkins, Julian Gillmore, Helen J Lachmann, Shameem Mahmood, Carol Whelan, Ashutosh D. Wechalekar

Blood (2023) 142 (Supplement 1): 537.

https://doi.org/10.1182/blood-2023-178243

Published: 2023

Journal Articles

Infection Risk and Use of Prophylaxis with Anti-BCMA Bispecific T Cell Engagers and Belantamab Mafodotin for Patients with Relapsed and Refractory Multiple Myeloma

Rakesh Popat, Kathleen Cheok, Amrutha Sridhar, Conor Feely, Catriona Mactier, Annabel Mcmillan, Ashutosh D. Wechalekar, Neil Rabin, Jonathan Sive, Charalampia Kyriakou, Ke Xu, Xenofon Papanikolaou, Shameem Mahmood, Kwee Yong, Lydia Sarah Hui Lee

Blood (2023) 142 (Supplement 1): 4702.

https://doi.org/10.1182/blood-2023-182725

Published: 2023

Journal Articles

Use of Matrix-Assisted Laser Desorption/Ionisation Time-of-Flight Mass Spectrometry (MALDI-TOF MS) Free Light Chain Assessment for the Diagnosis and Monitoring of Systemic Immunoglobulin Light Chain (AL) Amyloidosis

Blood (2022) 140 (Supplement 1): 2351–2353.

https://doi.org/10.1182/blood-2022-160018

Published: 2022

Journal Articles

General Patient-Reported Outcome Measure Tools Non-Reflective of AL Amyloidosis Quality of Life (QoL): A Systematic Literature Review

Sotirios Bristogiannis, Charalampia Kyriakou, Ashutosh Wechelaker, Brendan Wisniowski, Shameem Mahmood, Sajitha Sachchithanantham

Blood (2021) 138 (Supplement 1): 5007.

https://doi.org/10.1182/blood-2021-147021

Published: 2021

Journal Articles

Serological Response to the BNT162b2 mRNA or Chadox-Ncov-19 COVID-19 Vaccine after First and Second Doses in Plasma Cell Disorder Patients: Influence of Host and Disease Factors

Blood (2021) 138 (Supplement 1): 1628.

https://doi.org/10.1182/blood-2021-149027

Published: 2021

Journal Articles

The Prognostic Importance of the 6-Minute Walk Test in AL Amyloidosis

Oliver C Cohen, MBBS, BSc, FRCPath, Ananth Sathyanath, Sriram Ravichandran, MBBS, MRCP, FRCPath, Steven Law, MBBS, BSc, Richa Manwani, MBBS, FRCPath, BSc, Darren Foard, Sajitha Sachchithanantham, MBBS, BSc, FRCPath, Shameem Mahmood, Ana Martinez-Naharro, Marianna Fontana, Carol Whelan, Philip N Hawkins, Helen J Lachmann, Julian D Gillmore, Ashutosh D. Wechalekar, MBBS,FRCP,FRCPath,DM

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-137036

Published: 2020

Journal Articles

The Impact of Longitudinal Strain on Haematological and Cardiac Response and Survival in Patients with Systemic AL Amyloidosis

Oliver C Cohen, MBBS, BSc, FRCPath, Andreia Ismael, Richa Manwani, MBBS, FRCPath, BSc, Sriram Ravichandran, MBBS, MRCP, FRCPath, Steven Law, MBBS, BSc, Darren Foard, Ana Martinez-Naharro, Shameem Mahmood, Sajitha Sachchithananthan, Philip N Hawkins, Helen J Lachmann, Julian D Gillmore, Marianna Fontana, Rodney H Falk, MD, Carol Whelan, Ashutosh D. Wechalekar, MBBS,FRCP,FRCPath,DM

Blood (2020) 136 (Supplement 1): 40.

https://doi.org/10.1182/blood-2020-137391

Published: 2020

Journal Articles

A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib

Richa Manwani, Oliver Cohen, Faye Sharpley, Shameem Mahmood, Sajitha Sachchithanantham, Darren Foard, Helen J. Lachmann, Cristina Quarta, Marianna Fontana, Julian D. Gillmore, Carol Whelan, Philip N. Hawkins, Ashutosh D. Wechalekar

Blood (2019) 134 (25): 2271–2280.

https://doi.org/10.1182/blood.2019000834

Published: 2019

Journal Articles

Quantitative Immunoprecipitation Free Light Chain Mass Spectrometry (QIP-FLC-MS) Simplifies Monoclonal Protein Assessment and Provides Added Clinical Value in Systemic AL Amyloidosis

Faye Amelia Sharpley, BA MA MSc MBBChir FRCPath, Hannah Victoria Giles, FRCPath, MRCP, Richa Manwani, MBBS, FRCPath, BSc, Shameem Mahmood, Sajitha Sachchithanantham, Helen J Lachmann, MA MB BChir MDFRCP, Julian D Gillmore, MBBS, MD PhD FRCP, Carol J Whelan, Philip N Hawkins, Ashutosh D Wechalekar, MB BS, MD FRCP, FRCPath, DM

Blood (2019) 134 (Supplement_1): 4375.

https://doi.org/10.1182/blood-2019-128175

Published: 2019

Journal Articles

Subsequent Treatments, Responses and Survival in the Real World for Patients with Relapsed Multiple Myeloma Following Treatment with Lenalidomide

Jessica B Taube, MBBChir, Catherine SY Lecat, MBBS, Simon Cheesman, BPharm, Gabriel Wallis, Charalampia Kyriakou, Lydia Lee, Shameem Mahmood, Xenofon Papanikolaou, Christopher Parrish, MB BChir MA MRCP FRCPath PhD, Neil K Rabin, Sajitha Sachchithananthan, Jonathan Sive, MD, Ashutosh D. Wechalekar, Kwee Yong, Gordon Cook, Rakesh Popat

Blood (2019) 134 (Supplement_1): 4340.

https://doi.org/10.1182/blood-2019-128266

Published: 2019

Journal Articles

A Phase 1 Study of Carfilzomib-Thalidomide-Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis - Catalyst Trial Results

Mamta Garg, MD FRCP, FRCPath, Andrew Hall, Matthew Jenner, MBBS, MRCP, FRCPath, Bhuvan Kishore, MB BS, MRCP, FRCPath, Helen J Lachmann, MA MB BChir MDFRCP, Julian D Gillmore, MBBS, MD PhD FRCP, Alexandra Pitchford, Louise Flanagan, PhD, Jamie B Oughton, MPhil, BSc, Shameem Mahmood, Sajitha Sachchithanantham, Sarah R Brown, PhD MSc, BSc, Ashutosh D Wechalekar, MBBS, MD FRCP, FRCPath, DM

Blood (2019) 134 (Supplement_1): 1890.

https://doi.org/10.1182/blood-2019-126567

Published: 2019

Journal Articles

The UK Experience of Renal Transplantation in AL Amyloidosis

Oliver C Cohen, MB BS, BSc, FRCPath, Faye Sharpley, MBBChir, MA, MRCP, MSc, Julian Gillmore, Helen Lachmann, Shameem Mahmood, Sajitha Sachchithanantham, Carol Whelan, Ana Martinez De Azcona Naharro, Marianna Fontana, Philip Hawkins, Ashutosh D. Wechalekar

Blood (2019) 134 (Supplement_1): 2206.

https://doi.org/10.1182/blood-2019-128443

Published: 2019

Journal Articles

A Novel Mass Spectrometry Method to Identify the Serum Monoclonal Light Chain Component and Infer Organ Involvement in Systemic Light Chain Amyloidosis

Faye Sharpley, Richa Manwani, MBBS, FRCPath, BSc, Shameem Mahmood, Sajitha Sachchithanantham, Helen Lachmann, Julian Gillmore, Carol Whelan, Philip Hawkins, Ashutosh D. Wechalekar

Blood (2018) 132 (Supplement 1): 4445.

https://doi.org/10.1182/blood-2018-99-114028

Published: 2018

Journal Articles

Achieving a Difference in Involved and Uninvolved Light Chains (dFLC) of Less Than 10mg/L Is the New Goal of Therapy in Systemic AL Amyloidosis: Analysis of 916 Patients Treated Upfront with Bortezomib-Based Therapy

Richa Manwani, MBBS, FRCPath, BSc, Faye Sharpley, Shameem Mahmood, Sajitha Sachchithanantham, Helen Lachmann, Julian Gillmore, Carol Whelan, Philip Hawkins, Ashutosh D. Wechalekar

Blood (2018) 132 (Supplement 1): 3262.

https://doi.org/10.1182/blood-2018-99-116688

Published: 2018

Journal Articles

Pomalidomide and Dexamethasone Grant Rapid Hematologic Responses in Patients with Relapsed and Refractory AL Amyloidois: A European Retrospective Series of 150 Patients

Paolo Milani, MD, Faye Sharpley, Stefan Schönland, Marco Basset, MD, Shameem Mahmood, Christoph Kimmich, Andrea Foli, MD, Sajitha Sachchithanantham, Giampaolo Merlini, MD, Ashutosh D. Wechalekar, Giovanni Palladini, MD PhD, Ute Hegenbart

Blood (2018) 132 (Supplement 1): 3264.

https://doi.org/10.1182/blood-2018-99-118034

Published: 2018

Journal Articles

Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine

Richa Manwani, Sajitha Sachchithanantham, Shameem Mahmood, Darren Foard, Faye Sharpley, Tamer Rezk, Thirusha Lane, Cristina Quarta, Marianna Fontana, Helen J. Lachmann, Julian D. Gillmore, Carol Whelan, Philip N. Hawkins, Ashutosh D. Wechalekar

Blood (2018) 132 (7): 761–764.

https://doi.org/10.1182/blood-2018-04-846493

Published: 2018

NARROW

Defining a New “Mayo Stage IIIc” Ultra Poor Risk Category in Systemic AL Amyloidosis: Incorporating Echocardiographic Global Longitudinal Strain to the European Modified Mayo Staging System

Prognostication in IgM and Lymphoplasmacytic Lymphoma Associated Systemic AL Amyloidosis

Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis

High Responses Rates with Single Agent Belantamab Mafodotin in Relapsed Systemic AL Amyloidosis

Limited Utility of Mayo 2012 Cardiac Staging System for Risk Stratification of Patients with Advanced Cardiac AL Amyloidosis - Analysis of a Uniformly Treated Cohort of 1275 Patients

Infection Risk and Use of Prophylaxis with Anti-BCMA Bispecific T Cell Engagers and Belantamab Mafodotin for Patients with Relapsed and Refractory Multiple Myeloma

Use of Matrix-Assisted Laser Desorption/Ionisation Time-of-Flight Mass Spectrometry (MALDI-TOF MS) Free Light Chain Assessment for the Diagnosis and Monitoring of Systemic Immunoglobulin Light Chain (AL) Amyloidosis

General Patient-Reported Outcome Measure Tools Non-Reflective of AL Amyloidosis Quality of Life (QoL): A Systematic Literature Review

Serological Response to the BNT162b2 mRNA or Chadox-Ncov-19 COVID-19 Vaccine after First and Second Doses in Plasma Cell Disorder Patients: Influence of Host and Disease Factors

The Prognostic Importance of the 6-Minute Walk Test in AL Amyloidosis

The Impact of Longitudinal Strain on Haematological and Cardiac Response and Survival in Patients with Systemic AL Amyloidosis

A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib

Quantitative Immunoprecipitation Free Light Chain Mass Spectrometry (QIP-FLC-MS) Simplifies Monoclonal Protein Assessment and Provides Added Clinical Value in Systemic AL Amyloidosis

Subsequent Treatments, Responses and Survival in the Real World for Patients with Relapsed Multiple Myeloma Following Treatment with Lenalidomide

A Phase 1 Study of Carfilzomib-Thalidomide-Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis - Catalyst Trial Results

The UK Experience of Renal Transplantation in AL Amyloidosis

A Novel Mass Spectrometry Method to Identify the Serum Monoclonal Light Chain Component and Infer Organ Involvement in Systemic Light Chain Amyloidosis

Achieving a Difference in Involved and Uninvolved Light Chains (dFLC) of Less Than 10mg/L Is the New Goal of Therapy in Systemic AL Amyloidosis: Analysis of 916 Patients Treated Upfront with Bortezomib-Based Therapy

Pomalidomide and Dexamethasone Grant Rapid Hematologic Responses in Patients with Relapsed and Refractory AL Amyloidois: A European Retrospective Series of 150 Patients

Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only